Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis.
Fecal microbiota transplantation
Irritable bowel syndrome
Meta-analysis
Systematic review
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
28 May 2023
28 May 2023
Historique:
received:
22
02
2023
revised:
06
04
2023
accepted:
18
04
2023
medline:
26
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
ppublish
Résumé
Irritable bowel syndrome (IBS) is the most prevalent gastrointestinal disorder in developed countries and reduces patients' quality of life, hinders their ability to work, and increases health care costs. A growing number of trials have demonstrated an aberrant gut microbiota composition in IBS, also known as 'gut dysbiosis'. Fecal microbiota transplantation (FMT) has been suggested as a treatment for IBS. To assess the efficacy and safety of FMT for the treatment of IBS. We searched Cochrane Central, MEDLINE, EMBASE and Web of Science up to 24 October 2022 for randomised controlled trials (RCTs) investigating the effectiveness of FMT compared to placebo (including autologous FMT) in treating IBS. The primary outcome was the number of patients with improvements of symptoms measured using a validated, global IBS symptoms score. Secondary outcomes were changes in quality-of-life scores, non-serious and serious adverse events. Risk ratios (RR) and corresponding 95%CI were calculated for dichotomous outcomes, as were the mean differences (MD) and 95%CI for continuous outcomes. The Cochrane risk of bias tool was used to assess the quality of the trials. GRADE criteria were used to assess the overall quality of the evidence. Eight RCTs (484 participants) were included in the review. FMT resulted in no significant benefit in IBS symptoms three months after treatment compared to placebo (RR 1.19, 95%CI: 0.68-2.10). Adverse events were reported in 97 participants in the FMT group and in 45 participants in the placebo group (RR 1.17, 95%CI: 0.63-2.15). One serious adverse event occurred in the FMT group and two in the placebo group (RR 0.42, 95%CI: 0.07-2.60). Endoscopic FMT delivery resulted in a significant improvement in symptoms, while capsules did not. FMT did not improve the quality of life of IBS patients but, instead, appeared to reduce it, albeit non significantly (MD -6.30, 95%CI: -13.39-0.79). The overall quality of the evidence was low due to moderate-high inconsistency, the small number of patients in the studies, and imprecision. We found insufficient evidence to support or refute the use of FMT for IBS. Larger trials are needed.
Sections du résumé
BACKGROUND
BACKGROUND
Irritable bowel syndrome (IBS) is the most prevalent gastrointestinal disorder in developed countries and reduces patients' quality of life, hinders their ability to work, and increases health care costs. A growing number of trials have demonstrated an aberrant gut microbiota composition in IBS, also known as 'gut dysbiosis'. Fecal microbiota transplantation (FMT) has been suggested as a treatment for IBS.
AIM
OBJECTIVE
To assess the efficacy and safety of FMT for the treatment of IBS.
METHODS
METHODS
We searched Cochrane Central, MEDLINE, EMBASE and Web of Science up to 24 October 2022 for randomised controlled trials (RCTs) investigating the effectiveness of FMT compared to placebo (including autologous FMT) in treating IBS. The primary outcome was the number of patients with improvements of symptoms measured using a validated, global IBS symptoms score. Secondary outcomes were changes in quality-of-life scores, non-serious and serious adverse events. Risk ratios (RR) and corresponding 95%CI were calculated for dichotomous outcomes, as were the mean differences (MD) and 95%CI for continuous outcomes. The Cochrane risk of bias tool was used to assess the quality of the trials. GRADE criteria were used to assess the overall quality of the evidence.
RESULTS
RESULTS
Eight RCTs (484 participants) were included in the review. FMT resulted in no significant benefit in IBS symptoms three months after treatment compared to placebo (RR 1.19, 95%CI: 0.68-2.10). Adverse events were reported in 97 participants in the FMT group and in 45 participants in the placebo group (RR 1.17, 95%CI: 0.63-2.15). One serious adverse event occurred in the FMT group and two in the placebo group (RR 0.42, 95%CI: 0.07-2.60). Endoscopic FMT delivery resulted in a significant improvement in symptoms, while capsules did not. FMT did not improve the quality of life of IBS patients but, instead, appeared to reduce it, albeit non significantly (MD -6.30, 95%CI: -13.39-0.79). The overall quality of the evidence was low due to moderate-high inconsistency, the small number of patients in the studies, and imprecision.
CONCLUSION
CONCLUSIONS
We found insufficient evidence to support or refute the use of FMT for IBS. Larger trials are needed.
Identifiants
pubmed: 37346153
doi: 10.3748/wjg.v29.i20.3185
pmc: PMC10280798
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3185-3202Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: None of the authors report relevant conflicts of interest for this article.
Références
Gastroenterology. 2007 Jul;133(1):24-33
pubmed: 17631127
Gut. 2012 Jul;61(7):997-1006
pubmed: 22180058
Dig Dis Sci. 2020 Mar;65(3):829-839
pubmed: 32026278
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
JAMA. 2014 Nov 5;312(17):1772-8
pubmed: 25322359
Lancet Gastroenterol Hepatol. 2016 Sep;1(1):6-8
pubmed: 28404114
Gut. 2017 Apr;66(4):569-580
pubmed: 28087657
Neurogastroenterol Motil. 2005 Jun;17(3):332-40
pubmed: 15916620
Aliment Pharmacol Ther. 2017 Jan;45(2):222-239
pubmed: 27891639
Gastroenterology. 2021 Jan;160(1):145-157.e8
pubmed: 32681922
Neurogastroenterol Motil. 2015 Jan;27(1):19-29
pubmed: 25424663
Digestion. 2017;96(1):29-38
pubmed: 28628918
Nat Med. 2022 Sep;28(9):1913-1923
pubmed: 36109637
Am J Physiol Gastrointest Liver Physiol. 2016 Mar 15;310(6):G417-26
pubmed: 26702134
Microbiome. 2020 Feb 3;8(1):12
pubmed: 32014035
Front Med (Lausanne). 2022 Nov 11;9:1059148
pubmed: 36438048
Science. 2016 Apr 29;352(6285):586-9
pubmed: 27126044
J Acad Nutr Diet. 2020 Apr;120(4):565-586
pubmed: 31473156
Gastroenterology. 2015 Jul;149(1):223-37
pubmed: 25982290
Aliment Pharmacol Ther. 2020 Jun;51(12):1321-1331
pubmed: 32343000
J Neurosci. 2014 Nov 12;34(46):15490-6
pubmed: 25392516
JAMA. 2016 Jan 12;315(2):142-9
pubmed: 26757463
Am J Gastroenterol. 2012 Nov;107(11):1755; author reply p.1755-6
pubmed: 23160295
Neurogastroenterol Motil. 2021 Nov;33(11):e14157
pubmed: 34236740
World J Gastroenterol. 2017 Jun 14;23(22):4112-4120
pubmed: 28652664
Aliment Pharmacol Ther. 2018 Nov;48(10):1044-1060
pubmed: 30294792
Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4
pubmed: 22426087
Front Microbiol. 2019 Jun 10;10:1136
pubmed: 31244784
Gut. 2020 May;69(5):859-867
pubmed: 31852769
Lancet Gastroenterol Hepatol. 2018 Jan;3(1):17-24
pubmed: 29100842
Gut Microbes. 2020 Nov 9;12(1):1794263
pubmed: 32991818
United European Gastroenterol J. 2021 Mar;9(2):229-247
pubmed: 33151137
Cochrane Database Syst Rev. 2018 Nov 13;11:CD012774
pubmed: 30480772
Curr Gastroenterol Rep. 2009 Aug;11(4):265-9
pubmed: 19615301
EBioMedicine. 2019 Jun;44:716-729
pubmed: 31201141
Inflamm Bowel Dis. 2016 Sep;22(9):2182-90
pubmed: 27542133
Clin Transl Gastroenterol. 2019 Apr;10(4):e00034
pubmed: 31009405
Lancet. 1998 Oct 10;352(9135):1187-9
pubmed: 9777836
Aliment Pharmacol Ther. 2010 Jul;32(2):144-58
pubmed: 20412064
Gut. 2020 Jun;69(6):1076-1084
pubmed: 31601615
World J Gastroenterol. 2015 Mar 14;21(10):3072-84
pubmed: 25780308
Gut. 2019 Dec;68(12):2111-2121
pubmed: 31563878
Microorganisms. 2022 Nov 23;10(12):
pubmed: 36557570
Therap Adv Gastroenterol. 2021 Aug 31;14:17562848211041004
pubmed: 34484424
Mayo Clin Proc. 2014 Jan;89(1):107-14
pubmed: 24388028
Aliment Pharmacol Ther. 2014 May;39(10):1003-32
pubmed: 24641570
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
Aliment Pharmacol Ther. 2014 Nov;40(9):1023-34
pubmed: 25199904
J Clin Med. 2021 Sep 08;10(18):
pubmed: 34575166
Med J Aust. 1989 May 15;150(10):604
pubmed: 2783214
Lancet Gastroenterol Hepatol. 2019 Sep;4(9):675-685
pubmed: 31326345
Adv Ther. 2018 Mar;35(3):289-310
pubmed: 29498019
Eur J Clin Microbiol Infect Dis. 2017 Dec;36(12):2303-2317
pubmed: 28785822
Aliment Pharmacol Ther. 2013 Oct;38(8):864-86
pubmed: 23981066
World J Gastroenterol. 2014 Jul 21;20(27):8886-97
pubmed: 25083061
Am J Gastroenterol. 2005 Feb;100(2):373-82
pubmed: 15667495
Dig Liver Dis. 2017 Apr;49(4):331-337
pubmed: 28179092
FEMS Immunol Med Microbiol. 2005 Feb 1;43(2):213-22
pubmed: 15747442
Front Cell Infect Microbiol. 2021 May 12;11:524851
pubmed: 34055657
Aliment Pharmacol Ther. 2018 Feb;47(3):371-379
pubmed: 29226561
Aliment Pharmacol Ther. 2017 Aug;46(3):213-224
pubmed: 28612983
Infect Dis Ther. 2016 Jun;5(2):155-64
pubmed: 27048199
Gut Microbes. 2022 Jan-Dec;14(1):2020067
pubmed: 35014601
Aliment Pharmacol Ther. 2015 Jan;41(1):46-53
pubmed: 25355279
World J Gastroenterol. 2014 Jun 14;20(22):6759-73
pubmed: 24944467
Pharmaceuticals (Basel). 2022 Nov 13;15(11):
pubmed: 36422528
Gastroenterology. 2009 May;136(6):1979-88
pubmed: 19457422
Curr Gastroenterol Rep. 2017 Apr;19(4):15
pubmed: 28374308
J Clin Gastroenterol. 2004 Jul;38(6):475-83
pubmed: 15220681
Gut. 2018 Dec;67(12):2107-2115
pubmed: 29980607
Expert Rev Gastroenterol Hepatol. 2018 May;12(5):439-445
pubmed: 29493330
EClinicalMedicine. 2020 Nov 23;29-30:100642
pubmed: 33437951
Clin Endosc. 2016 May;49(3):257-65
pubmed: 26956193